Skip to content

Effectiveness research of Q'sai "Aojiru", against metabolic syndrome.

Effectiveness research of Q'sai "Aojiru", against metabolic syndrome. - Intake effect of Q'sai "Aojiru"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009408
Enrollment
60
Registered
2012-12-01
Start date
2013-01-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Interventions

Intake of &quot
Aojiru&quot

Sponsors

Q'SAI CO,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Habitants who took a medical check in Arita 2) Person who are age from 30 to 74. 3) Person who correspond to the following at least one items. 1.Waist Male >= 85cm Female>=90cm 2.Fasting triglyceride >= 150mg/dL and/or HDL Cholesterol < 40mg/dL 3. SBP >= 120mmHg and/or DBP >= 80mmHg 4.Fasting Blood Sugar >= 110mg/dL 5. BMI >= 25kg/m2 6.LDL Cholesterol>=120mg/dL 4) Person who can consume the product continuously.

Exclusion criteria

Exclusion criteria: 1) Person who takes regularly health care products including Q'sai "Aojiru" and other products . 2) Person whose latest clinical laboratory test results are significantly out of standard value and an investigator determined that he/she is required to take treatment. 3) Person who get an atrial fibrillation 4) Person who has critical disease history such as cardiac disease, cerebrovascular disease, kidney disease 5) Person who take warfarin potassium 6) Person who has allergies to plants of the Brassicaceae, including Kale. 7) Person who participated another clinical investigation or trial within 2 months from the start date of this study. 8) With other factors, an investigator determines that a person is unfit to participate the study.

Design outcomes

Primary

MeasureTime frame
Blood pressure Neutral fat, LDL Cholesterol, HDL cholesterol, Fasting Blood Sugar, HbA1c, Body Mass Index, Waist, Evaluated at the time of registration, intake start and end in 8 week.

Secondary

MeasureTime frame
Questionnaire on feeling effectiveness. Evaluated at the time of registration, at the time of an intake start and end in 8 week.

Countries

Japan

Contacts

Public ContactHisami Inuduka

Hubit genomix, Inc. Business Promotion Unit

hinuzuka@hubitgenomix.com0955-43-3334

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026